Registry update — unassessed
Senolytics as a Novel Treatment for Interstitial Lung Disease in Common Variable Immunodeficiency (CVID)
Trial registry update: ACTIVE_NOT_RECRUITING. No results reported in the supplied registry record.
RCTRoutine significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Jun 30, 2026 · Discovered: Sep 15, 2026 · Assessed: — · Historical research backfill
What it does not prove
- The abstract provides no efficacy data, making it impossible to determine whether fisetin had any effect on CVID-related lung disease.
- It is unclear whether this trial was completed, what outcomes were measured, or whether results favoured the intervention or placebo.
- No information is available on safety, tolerability, or suitability for clinical use.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- Common variable immunodeficiency (CVID) patients with interstitial lung disease
- Primary outcome
- Efficacy of Fisetin as treatment for CVID
- Effect size
- —
- Significance
- Not reported
- Journal
- Avni Joshi
- Published
- Jun 30, 2026
Sources
Primary source
- Avni Joshi ↗Clinical trial
Recorded source passages
Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.
Title: Senolytics as a Novel Treatment for Interstitial Lung Disease in Common Variable Immunodeficiency (CVID)
Abstract: The purpose of this study is to determine if the supplement, Fisetin, can be used as a treatment option for common variable immunodeficiency (CVID) by comparing its efficacy to placebo.
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.